ENTA Stock — Enanta Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$12.20

Market cap

$355.3M

Cash

$189.5M

Enterprise value

$165.8M

Balance sheet

Cash	$189.5M
Debt	$0.0M
Net cash	$189.5M
Enterprise value	$165.8M
Basic shares	29.1M shares
Fully diluted shares	36.4M shares
Fully diluted market cap	$444.3M
Cash per share	$6.51

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ENTA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	EDP-978	Phase 1	Chronic Inducible Urticaria; Chronic Spontaneous Urticaria	—
Jan 12 - Feb 23	zelicapavir	Phase 2	RSV Infection; RSV; Respiratory Syncytial Virus (RSV)	2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

zelicapavir

Phase 2 · Active Modality: small molecule (oral, once-daily)

Aliases EDP-938

Target RSV N-protein

Indications

Respiratory syncytial virus (RSV) in high-risk adults (Phase 2)
RSV in pediatric patients (28 days to 36 months) (Phase 2)

Catalysts

— Q4 2026
— 2027
— 2027

Status note Lead program. FDA Fast Track for RSV. Positive Phase 2b topline in high-risk adults (Sep 2025) and Phase 2 in pediatrics (Dec 2024). RESOLVE and LOTUS (first participant dosed Q3 2026) are the named next trials; company is exploring business development for RSV programs.

EDP-323

Phase 2 · Active Modality: small molecule (oral, once-daily)

Target RSV L-protein

Indications

Respiratory syncytial virus (RSV) (Phase 2)

Status note FDA Fast Track for RSV. Positive Phase 2a challenge study topline (Sep 2024), including post-exposure prophylaxis signal. No next trial details stated; development focus is on zelicapavir.

EDP-978

Phase 1 · Active Modality: small molecule (oral, once-daily)

Target KIT

Indications

Chronic spontaneous urticaria (CSU) (Phase 1)

Catalysts

— Q4 2026

Status note Clinical immunology candidate targeting mast cell depletion; Phase 1 in healthy volunteers dosed first participant April 2026; potential expansion to other mast cell-associated indications.

EPS-3903

Preclinical · Active Modality: small molecule (oral)

Target STAT6

Indications

Atopic dermatitis (AD) (Preclinical)

Catalysts

— 2H 2026

Status note Preclinical lead candidate in STAT6 inhibitor program; initial proof-of-concept planned in AD, then other indications where IL-4/IL-13 pathway blockade applies. IND-enabling/scale-up ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	zelicapavir
Lead indication	RSV Infection
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07482657	Phase 2	Recruiting	Sponsor	ENTA	—	RSV Infection; RSV; Respiratory Syncytial Virus (RSV)	2027
NCT07540910	Phase 1	Recruiting	Sponsor	ENTA	—	Chronic Inducible Urticaria; Chronic Spontaneous Urticaria	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Enanta Pharmaceuticals, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,344,510	+1,293,153	0.92%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ENTA — Enanta Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders